Send SMS
08045812201

Fabiflu 200/400mg

Fabiflu 200/400mg

Product Details:

  • Drug Type General Medicines
  • Ingredients Favipiravir 200/400mg
  • Physical Form Tablets
  • Function Anti-Viral
  • Recommended For covid -19
  • Dosage twice a day
  • Dosage Guidelines twice a day
  • Supply Ability : 100000 Box Per Week
1 USD ($)/Box
X

Price And Quantity

  • 500 Box
  • 1 USD ($)/Box
  • 15.00 - 30.00 USD ($)/Box

Product Specifications

  • Anti-Viral
  • Women, Adults, Aged Person
  • any place
  • General Medicines
  • covid -19
  • Tablets
  • twice a day
  • Favipiravir 200/400mg
  • twice a day
  • 5000 Boxes

Trade Information

  • surat
  • Cash Advance (CA), Cash in Advance (CID), Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Western Union, Paypal
  • 100000 Box Per Week
  • 3 Days
  • Yes
  • Contact us for information regarding our sample policy
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • All India

Product Description

Favipiravir inhibited the replication of viral genome, which was the most manifested in the middle of viral proliferation cycle in a time-of-drug-addition test, Anti-viral activity of favipiravir was attenuated in the presence of purine nucleosides or purine bases, indicating competition of favipiravir with purine nucleosides rather than pyrimidine nucleosides. Madin Darby Canine Kidney (MDCK) cells are well used as an in vitro assay of influenza virus. MDCK cells were treated with favipiravir, and cellular metabolites were analyzed by HPLC. Favipiravir ribofuranosyl-5′-triphosphate (favipiravir-RTP), favipiravir ribofuranose (favipiravir-R) and favipiravir ribofuranosyl-5′-monophosphate (favipiravir-RMP) were detected.These results suggest that the activation of favipiravir takes place once it is incorporated into cells. Favipiravir-RTP was chemically synthesized and was tested for the inhibition of RNA polymerase activity of influenza virus as assessed by incorporation of P-GTP. Favipiravir-RTP inhibited the viral RNA polymerase activity in concentrations ranging from nanomolar to micromolar. None of favipiravir and favipiravir-RMP affected influenza RNA-dependent RNA polymerase (RdRp) at 100 µmol/L These results indicate that favipiravir exerts its anti-viral activity as a pro-drug, since favipiravir is intra-cellularly phosphoribosylated to be an active form, favipiravir-RTP, which inhibits the viral replication by interacting with viral RNA polymerase.
Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'Pharmaceutical Products' category



Back to top